Greater Prevalence of Diabetes Holds a Cascading Impact on Diabetic Foot Complications
Diabetes mellitus, one of the leading chronic ailments worldwide and among the top mortality causes, is especially complicated because of its close association with a number of other threatening conditions. Diabetic foot ulceration is one such devastating consequence that tends to afflict roughly 15% of the total diabetic population (Bakker et al), and most likely develops at least once in lifetime after diagnosis. It is also a prominent component of the diabetic foot syndrome. The findings of the Centers for Disease Control and Prevention (CDC) show that in 2017, over 100 million people were living with diabetic or prediabetic conditions in the US alone. Moreover, WHO affirms that the world sees over a million deaths because of a condition associated with diabetes. With the constantly expanding population of diabetic patients, elderly people with other comorbidities and are those at a greater risk of diabetes, the likelihood of them getting bruises, ulcers, and other diabetic foot complications also rises. This predominantly drives the expansion of the diabetic foot ulcers treatment market.
A Close Correlation Between Diabetic Foot Ulcers and Amputations Needs Critical Treatment Alternatives
The recently published D-Foot International stats have revealed some alarming global facts, and figures. Every 20 seconds, diabetes becomes the reason for a lost limb (through amputation). While the diabetic population is around 10-20X more prone to the need for an amputation over the non-diabetic population, the former can also experience nerve damage in feet that consequently brings down their sensation toward injuries. This ultimately results in foot ulceration. About a whopping 80% of the diabetic patient population tends to experience peripheral diabetic neuropathy at some point or the other, and nearly 25% of them are at a high risk of developing foot ulcers.
Up to 85% of all the amputations of lower limb are observed to be preceded by a foot ulcer, which significantly reduces the life expectancy. As ulcers pose a massive risk to the quality of life by making the patients highly susceptible to any kind of infections, there remains a significant need for effective wound management, and specifically diabetic foot ulcers treatment. An increasing level of awareness among diabetic patients about early detection of bruises, and ulcers to get them treated at the earliest will be an important factor responsible for the growth of the diabetic foot ulcers treatment market.
Ulcer-specific Wound Care Dressings to Capture Spotlight
Higher probability of diabetic neuropathy among patients remains the key factor fuelling prevalence of neuropathic ulcers. While non-surgical treatment is highly preferred for non-infected ulcers, it has been shown to be relatively ineffective, which increases the scope for penetration of the various surgical intervention alternatives. Wound care dressing, especially polyurethane foam dressing, continues to be in demand but podiatry specialists continue to seek a more reliable treatment option for effectively treating diabetic foot ulcers so that the patients experience a better quality of life. Hospital acquired pressure ulcers are also common among diabetic patients, further boosting the demand for treatment. Growing availability of ulcer-specific dressings to promote healing of specific ulcer types is anticipated to act as a solid factor fostering market growth during the forecast period.
Clinical Trials to Remain Key Growth Catalysts for Market
There are several clinical trials in pipeline and are expected to deliver positive results against diabetic foot ulcers, which is in favour of market growth. So far, the clinical trials with Apligraf, Dermagraft, and Lamin gel have turned out to be successful with some really favourable outcomes that can aid in diabetic foot ulcers treatment. This and more such technological advancements also continue to play out as the key support factors for the diabetic foot ulcers treatment market. Key companies have been actively partaking in development of novel diabetic foot ulcer therapeutics by enlarging their investments in extended research programmes. Newer therapies continue to make their debut in the market, driven by consistently advancing technologies that push the next-generation diabetic foot ulcers treatment options like bioengineered skin substitutes, miscellaneous therapeutic agents, and extracellular matrix proteins. However, expensive treatments currently seem to be limiting rapid expansion of the market.
COVID-19 Has Caused a Major Delay in Threatening Diabetic Foot Ulcers Treatment
One of the most harshly hit segments during the global COVID-19 pandemic is the non-communicable disease care. Although diabetes care is also one of the key areas affected, telemedicine rapidly emerged as a lucrative solution in front of diabetic patients. However, the associated, more severe conditions like diabetic food ulcers continue to remain a major challenge for both patients, and physicians as it exclusively requires hands-on treatment. The US Surgeon General, the Centers for Medicare and Medicaid Services (CMS), and the American College of Surgeons had recommended cancellation, or delaying of all the non-emergency medical, and surgical services in March, 2020. While this led to an immediate, drastic decline in everything related to non-emergency procedures, a majority of healthcare resources were reallocated to COVID-19 management duties.
Though the (chronic) wound care segment was temporarily dropped out of the non-essential category, the reluctance among diabetes foot ulcer patients retained almost through the peak pandemic period in 2020 as patients were terrified to physically visit their doctors, and raise the risks of getting exposed to the infection at hospitals. Even the dedicated wound care centres that are now operating with their 100% capacity still continue to face a remarkable drop of up to 40% in the patient footfall, clears the data presented by Today’s Wound Clinic. However, the fact is that the patients living with diabetic foot ulcers must receive prompt treatment from a professional foot protection team that ensures appropriate diabetic foot management. Late referrals of such patients may result in notably falling life expectancy for them, especially in cases of limb amputation. The diabetic foot ulcers treatment market has thus been facing severe impact of the viral outbreak.
Key Market Players
Medtronic Plc, B. Braun Melsungen AG, 3M Healthcare, Coloplast A/S, Organogenesis, Inc., Smith & Nephew plc, Derma Sciences Inc., Acelity L.P. Inc., Sigvaris Inc., Mölnlycke Health Care AB, Osiris, BSN Medical GMBH, Organogenesis, Inc., Acelity L.P. Inc., Mölnlycke Health Care AB, ConvaTec Group Plc, Medline Industries, Inc., Orpyx Medical Technologies Inc, Cardinal Health., Tissue Regenix, Wuhan Huawei Technology Co., Ltd., Changzhou Recoo Healthcare Co., Ltd., and Huizhou Foryou Medical Devices Co., Ltd.
Recent Notable Developments in Diabetic Foot Ulcers Treatment Market
Key Elements Included In The Study: Global Diabetic Foot Ulcers Treatment Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.View Methodology